AMLX - Why Is Neurodegenerative Diseases-Focused Amylyx Pharmaceuticals Stock Plunging On Friday? | Benzinga
Friday, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) announced topline results from the PHOENIX Phase 3 trial of AMX0035, also known as Relyvrio in the U.S. and Albrioza in Canada for amyotrophic lateral sclerosis (ALS).
PHOENIX did not meet its primary endpoint of reaching statistical significance (p=0.667) as measured by change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score at Week 48, nor was there statistical significance seen in secondary endpoints.
ALSFRS-R is a disease-specific severity score that reflects motor impairment and functional deterioration in ALS patients.
Amylyx will continue to engage with regulatory authorities to ...